Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)

St. Jude Reference #SJ-14-0019 / UTA 14-01

Description

Researchers have developed a hybrid compound that prevents metronidazole and similar antibiotics from being absorbed by the body before reaching the location of infection, thus avoiding the toxicity associated with higher doses of metronidazole. These hybrid compounds are not only effective in treating C. diff but other bacterial and parasitic infections such as Clostridium perfringen and Helicobacter pylori, and potentially Crohn’s disease and other inflammatory bowel diseases. This technology is being actively marketed by the co-owner, the University of Texas, Arlington.


 

Keywords

Colostridium Difficile, Chrohn’s, IBS


 

Granted Patents or Published Applications


 

 

Licensing Opportunities

Please contact us or UT Arlington (otm@uta.edu) if interested in licensing

Related Links

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.